Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids.
The endothelial cell-type plasminogen activator inhibitor (PAI-1) may exist in an inactive, latent form that can be converted into an active form upon treatment of the protein with denaturants, such as sodium dodecyl sulfate, guanidine HCl, or urea. The present paper demonstrates that latent PAI-1 can be activated by lipid vesicles containing the negatively charged phospholipids phosphatidylserine (PS) or phosphatidylinositol. The presence of a net negative charge on the phospholipid headgroup is essential for activation, since lipid vesicles consisting exclusively of zwitterionic phospholipids, such as phosphatidylcholine and phosphatidylethanolamine, do not activate PAI-1. In the presence of PS vesicles, PAI-1 inhibited tissue-type plasminogen activator 50-fold more effectively than in the absence of phospholipids, whereas sodium dodecyl sulfate enhanced PAI-1 activity by 25-fold. In mixed phospholipid vesicles containing PS and phosphatidylcholine in various molar ratios, the extent of PAI-1 activation was directly related to the PS content of the phospholipid membrane. Ca2+ ions interfered with the inhibitory activity of PS-activated PAI-1, suggesting that Ca2+ ions may regulate PAI-1 activity in the presence of negatively charged phospholipids. An important consequence of these findings is that, as in blood coagulation, negatively charged phospholipids may play an important regulatory role in controlling the fibrinolytic system by activating an inhibitor of tissue-type plasminogen activator.
D002122:Calcium Chloride / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005342:Fibrinolysis; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D010713:Phosphatidylcholines / Q000494:pharmacology; D010718:Phosphatidylserines / Q000494:pharmacology; D010743:Phospholipids / Q000494:pharmacology*; D015849:Plasminogen Inactivators; D012967:Sodium Dodecyl Sulfate / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000037:antagonists & inhibitors*
D006023:Glycoproteins; D010713:Phosphatidylcholines; D010718:Phosphatidylserines; D010743:Phospholipids; D015849:Plasminogen Inactivators; D012967:Sodium Dodecyl Sulfate; D010959:Tissue Plasminogen Activator; D002122:Calcium Chloride